About Us - Mitosol®

Mobius Therapeutics™ vision is to lead in ophthalmic perioperative pharmaceuticals. Our mission is to identify challenging needs and innovate solutions to improve patient care, patient access, and provider safety.

MITOSOLVED.™

Glaucoma surgery is done in a highly regulated environment and new USP <800> standards bring more vigilance to the usage and disposal of hazardous drugs, like mitomycin C, in the ophthalmic surgical arena. Additionally, glaucoma surgery requires supplies to be state of the art, reliable, and readily available, so that the surgical suite can run like a well-oiled machine.

Fortunately, MITOSOL has it all.

Mobius Therapeutics™ offers the first and only FDA-approved ophthalmic formulation of MMC. Mitosol (mitomycin for solution) Kit for Ophthalmic Use is an antimetabolite indicated as an adjunct to ab externo glaucoma surgery. It can be stored at room temperature for up to 24 months, is ready on demand and is reconstituted in a closed system that’s USP <800> compliant. In short, MITOSOL has created a new standard of care in glaucoma surgery.

In May 2025, Mobius Therapeutics became a wholly owned subsidiary of Glaukos Corporation, a global leader in ophthalmic pharmaceuticals and medical technologies. This acquisition marks an exciting step forward in our mission to support better surgical outcomes for patients with glaucoma.

As part of Glaukos, we continue to provide Mitosol^® with the same commitment to safety, quality, and innovation. We’re proud to be part of an organization that shares our passion for advancing eye care.

Learn more about Glaukos at glaukos.com.

INDICATION

Mitosol^® (mitomycin for solution) 0.2 mg/vial Kit for Ophthalmic Use is an antimetabolite indicated as an adjunct to ab externo glaucoma surgery.

Dosage & Administration

Mitosol^® is intended for topical application to the surgical site of glaucoma filtration surgery and must be reconstituted prior to application. Sponges provided within the Mitosol^® kit should be fully saturated with the entire reconstituted contents in a manner prescribed in the Instructions For Use. The sponge(s) should be applied to the treatment area for two minutes. Reconstituted Mitosol^® should be used within one hour of reconstitution.

US Patents #7,806,265, #8,186,511, #D685,962, #D685,963, #9,205,075, #9,539,241 and #9,649,428; other international patents issued and pending.

Product Information

IMPORTANT SAFETY INFORMATION

Contraindications

Mitosol^® is contraindicated in patients that have demonstrated a hypersensitivity to mitomycin in the past.

Warnings & Precautions

Cell Death: Mitomycin is cytotoxic. Use of mitomycin in concentrations higher than 0.2 mg/mL or use for longer than 2 minutes may lead to unintended corneal and/or sclera damage including thinning or perforation. Direct contact with the corneal endothelium will result in cell death. Hypotony: The use of mitomycin has been associated with an increased instance of post-operative hypotony. Cataract Development: Use in phakic patients has been correlated to a higher instance of lenticular change and cataract formation. Embryo-Fetal Toxicity: Can cause fetal harm. Advise of potential risk to a fetus. Verify pregnancy status in females of reproductive potential prior to use.

Adverse Events & Reactions

The most frequent adverse reactions to Mitosol^® occur locally and include hypotony, hypotony maculopathy, blebitis, endophthalmitis, vascular reactions, corneal reactions, and cataract.

You are encouraged to report all side effects to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You may also call Glaukos at 1-888-404-1644.